Author:
Mertens Laura S,van der Heijden Michiel S
Reference10 articles.
1. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000
2. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study;Pfister;Lancet Oncol,2023
3. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial;Pfister;J Clin Oncol,2022
4. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomized controlled trials;Burdett;Eur Urol,2022
5. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Powles;Ann Oncol,2022